Sumitomo Pharma Co Ltd 2021 IR
The report highlights Sumitomo Dainippon Pharma's progress in fiscal 2020, including achieving all-time high revenue of 516.0 billion yen and establishing a post-LATUDA growth engine through its strategic alliance with Roivant Sciences. The company revised its Basic Environmental Policies to commit to net-zero greenhouse gas emissions by fiscal 2050. Additionally, it introduced unique KPIs to measure progress on material issues and promoted digital transformation across its operations. The company also announced its trade name change to Sumitomo Pharma, effective April 1, 2022.
Company: Sumitomo Pharma Co Ltd
Sector: Health Care
Country: Japan
Year: 2021
Type: IR
Pages: 178
Sumitomo Pharma Co Ltd
Integrated Report
The report highlights Sumitomo Dainippon Pharma's progress in fiscal 2020, including achieving all-time high revenue of 516.0 billion yen and establishing a post-LATUDA growth engine through its strategic alliance with Roivant Sciences. The company revised its Basic Environmental Policies to commit to net-zero greenhouse gas emissions by fiscal 2050. Additionally, it introduced unique KPIs to measure progress on material issues and promoted digital transformation across its operations. The company also announced its trade name change to Sumitomo Pharma, effective April 1, 2022.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Net Zero Target
Employees